Category: Include on Menu
-
Hope Bancorp shares climb after second-quarter revenue tops estimates
Hope Bancorp, Inc. (NASDAQ:HOPE) shares rose nearly 5% in premarket trading on Monday after the bank holding company reported second-quarter revenue that exceeded Wall Street expectations while earnings matched analyst forecasts. The results reflected higher lending activity, expanding margins and continued improvements in profitability. Revenue beats forecasts as earnings meet expectations Hope Bancorp posted adjusted…
-
AMC reports record IMAX ticket sales following strong opening for The Odyssey
AMC Theatres (NYSE:AMC) announced that The Odyssey has delivered the highest IMAX box office revenue ever recorded at its cinemas during the first two weekends of a film’s release. The record covers the period from July 16 through July 26 and highlights strong demand for premium large-format screenings. Blockbuster opening drives IMAX performance The Odyssey…
-
NANO Nuclear Energy shares gain after securing U.S. Air Force contract
NANO Nuclear Energy Inc. (NASDAQ:NNE) shares rose 4% on Monday after the company announced it had been selected for a Small Business Innovation Research (SBIR) Phase I contract through AFWERX. The award supports development of the company’s KRONOS MMR™ Energy System as part of efforts to address operational challenges for the U.S. Department of the…
-
Circle shares rise after acquiring IBM’s blockchain patent portfolio
Circle Internet Group (NYSE:CRCL) shares gained 3.7% on Monday after the company announced it had acquired IBM’s blockchain patent portfolio, significantly expanding its intellectual property holdings in digital asset and blockchain technologies. According to the company, the acquisition includes more than 680 patent families and nearly 1,000 issued patents worldwide covering a broad range of…
-
Capricor Therapeutics shares plunge after FDA releases briefing documents
Capricor Therapeutics (NASDAQ:CAPR) shares dropped 40% on Monday after the U.S. Food and Drug Administration published briefing documents ahead of an upcoming advisory committee meeting to review the company’s lead cell therapy candidate. The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee is scheduled to meet on July 29 to evaluate Capricor’s resubmitted Biologics License…
-
HBT Financial beats second-quarter earnings and revenue forecasts
HBT Financial Inc. (NASDAQ:HBT) reported second-quarter results that exceeded Wall Street expectations on both earnings and revenue, as the regional bank benefited from stronger net interest income and its recent acquisition of CNB Bank Shares. The company posted adjusted earnings per share of $0.78, ahead of analysts’ consensus estimate of $0.73. Revenue reached $80.89 million,…
-
Rocket Lab shares climb after securing record U.S. Space Force launch contract
Rocket Lab (NASDAQ:RKLB) shares gained 5% on Monday after the aerospace company announced it had been awarded a $266 million launch agreement by the U.S. Space Force, the largest launch contract in the company’s history. The deal calls for Rocket Lab to carry out 12 suborbital launches, with the potential for up to six additional…
-
Lakeland Financial posts earnings beat despite revenue shortfall
Lakeland Financial Corporation (NASDAQ:LKFN) reported second-quarter results that exceeded earnings expectations but delivered revenue below Wall Street forecasts, as the regional bank continued to benefit from loan growth and a stronger net interest margin. The company posted adjusted earnings per share of $1.13, topping analysts’ consensus estimate of $1.08. Revenue totaled $70.9 million, missing the…
-
Alliance Resource Partners tops revenue estimates despite earnings miss
Alliance Resource Partners, L.P. (NASDAQ:ARLP) reported mixed second-quarter results on Monday, delivering revenue above Wall Street expectations while earnings came in slightly below forecasts. Shares of the coal producer and energy royalty company edged 0.16% higher in pre-market trading following the earnings release. Adjusted earnings per unit came in at $0.61, falling short of analysts’…
-
Gossamer Bio shares jump after FDA update and seralutinib rights return
Gossamer Bio Inc. (NASDAQ:GOSS) shares surged 25% on Monday after the biotechnology company provided a positive regulatory update on its lead drug candidate, seralutinib, and announced it had regained full global rights to the therapy. The clinical-stage drug developer said it recently completed a Pre-NDA Type B meeting with the U.S. Food and Drug Administration,…